A peptide news feed that treats sources with respect
We keep the stream editorial and source-first: regulatory updates, clinical developments, and research headlines, without mixing them into sales-y ticker copy.
FDA Warns Consumers About Unapproved Compounded GLP-1 Drug Products
The FDA issued a safety communication urging consumers not to use compounded semaglutide or tirzepatide products that have not been approved or authorised by the agency. The announcement follows reports of adverse events including nausea, hypoglycaemia, and hospitalisation.
FDA Approves First Oral GLP-1 Receptor Agonist for Type 2 Diabetes
The US Food and Drug Administration approved the first oral once-daily GLP-1 receptor agonist for glycaemic control in adults with type 2 diabetes, representing a significant shift in the delivery method for this class of metabolic peptide therapeutics.
FDA Issues Guidance on Peptide Drug Substance Nomenclature for INDs
New FDA guidance clarifies naming conventions and characterisation requirements for peptide drug substances in Investigational New Drug applications, aiming to reduce application deficiencies and streamline the review process for peptide-based therapeutics.